COVID Cases Increase, BPOM Approves Inavac Vaccine as a Booster

VIVA – After three years in Indonesia, COVID-19 cases have increased again along with reports of the entry of the Sub Omicron XBB variant. Based on reports as of November 22, 2022, the total death cases of new COVID-19 in Indonesia reached 51 people. 

Baca Juga

BPOM Bongkar Produksi Kosmetik Ilegal di Mojokerto: Senilai Rp16 Miliar

Therefore, this is a reminder for the government and the public not to forget about the pandemic situation in Indonesia.

The implementation of health protocols and vaccination is one of the ways to prevent the spread of COVID-19. Then, the Food and Drug Administration (BPOM) approves an Emergency Use Authorization (EUA) for the Inavac Vaccine to be used as a booster vaccine.

Baca Juga

BPOM Anggarkan Rp 509 Miliar pada 2027 Buat Awasi MBG

The Inavac vaccine is one of the COVID-19 vaccines developed domestically using the inactivated virus vaccine platform. This vaccine was developed by Airlangga University researchers in collaboration with PT Biotis Pharmaceuticals Indonesia.



Ilustrasi vaksin COVID-19.

Photo :

• Pexels/Maksim Goncharenok

Baca Juga

Strategi Novo Indonesia Dorong Masyarakat Berperan Aktif Memastikan Keamanan Penggunaan Obat

The issuance of EUA for the Inavac Vaccine as a booster vaccine has been carried out by the requirements, namely by first going through an evaluation process on the efficacy and safety aspects of the Inavac Vaccine for heterologous booster administration. The evaluation conducted by BPOM refers to the internationally accepted COVID-19 vaccine evaluation standards.

For 18 Years Old and Over

As information, the approved use of the Inavac Vaccine booster is as a heterologous booster vaccine with the primary Sinovac Vaccine in adults aged 18 years and over, which is given in 1 injection dose (5 mcg/0.5 mL) with an interval of at least 6 months after the complete primary dose using Sinovac Vaccine.

"Previously on November 1, 2022, BPOM had issued a EUA for Inavac Vaccine as a 2-dose primary vaccine for adults aged 18 years and over. With the approval of the Inavac Vaccine EUA for use as a booster vaccine, it adds to the booster vaccine alternatives for adults aged 18 years and over who have received primary vaccination using Sinovac Vaccine," Head of BPOM Indonesia, Penny K Lukito said.

Halaman Selanjutnya

Meanwhile, the efficacy and safety of the Inavac Vaccine as a heterologous booster refers to a clinical study using a vaccine comparator from an inactivated virus platform that has been approved as a booster vaccine.